Clinical trials: Cyclophosphamide
Breast Cancer
Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer
The purpose of this study is to analyze gene expression signature and immunohistochemical markers associated with clinical and pathological response to neoadjuvant chemotherapy in locally advanced breast cancer.
- Trial name
- LABC (NCT00820690)
- Testing
- doxorubicin, cyclophosphamide, paclitaxel
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- Barretos Cancer Hospital
Systemic Wegener's Granulomatosis
WEGENT - Comparison of Methotrexate or Azathioprine as Maintenance Therapy for ANCA-Associated Vasculitides
Remission of ANCA-associated vasculitis can be obtained in approximately 80% of the patients with a combination of corticosteroids and cyclophosphamide. However, relapses are frequent.
- Trial name
- NCT00349674
- Testing
- Azathioprine: 2 mg/kg/day, methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week
- Where
- France
- Volunteers
- 126 people
- Sponsor
- Hospices Civils de Lyon
Graft-versus-host-disease, Prophylaxis
Low Dose ATG Plus Low Dose PTCy as GVHD Prophylaxis in Haplo-HSCT
Low dose Rabbit Antithymocyte Globulin plus Low-dose post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical hematopoietic stem cell transplantation for patients with hematologic…
- Trial name
- ATG/PTCy (NCT03395860)
- Testing
- ATG
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Recurrent, Platinum-resistant
"Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This is a phase I clinical study for patients with platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal cancer, and the response to a combination of cyclophosphamide, autologous tumor-infiltrating…
- Conditions
- Recurrent, Platinum-resistant, High Grade Serous Ovarian Cancer, Fallopian Tube Cancer
- Trial name
- NCT01883297
- Testing
- Re-stimulated tumor-infiltrating lymphocytes (TILs), Interleukin-2, Cyclophosphamide
- Where
- Canada
- Volunteers
- 3 people
- Sponsor
- University Health Network, Toronto
Breast Cancer
Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2
Randomized phase II trial to study the effectiveness of chemotherapy with paclitaxel and the monoclonal antibody trastuzumab followed by chemotherapy in treating women who have stage II or stage IIIA breast cancer that…
- Trial name
- NCT00003992
- Testing
- trastuzumab, cyclophosphamide, doxorubicin hydrochloride
- Where
- 45 sites in United States, South Africa
- Volunteers
- 200 people
- Sponsor
- National Cancer Institute (NCI)
B-Chronic Lymphocytic Leukemia
Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia
This study aims to assess the rate of complete and overall response using rituximab and pentostatin with and without cyclophosphamide, to monitor and assess toxicity of this regimen, and to determine the overall and…
- Trial name
- NCT00201721
- Testing
- Pentostatin, Rituximab, Cyclophosphamide
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Triple Negative Breast Cancer, Vitamin D Deficiency
Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients
A two arm pilot study investigating the rate of pathologic complete response in patients with vitamin D deficiency and triple negative breast cancer undergoing standard neoadjuvant chemotherapy + vitamin D supplementation…
- Conditions
- Triple Negative Breast Cancer, Vitamin D Deficiency, Invasive Breast Cancer
- Trial name
- NCT04677816
- Testing
- Standard of Care Neoadjuvant Chemotherapy (NAC), Vitamin D3, Drug Diary
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Wake Forest University Health Sciences
Small Cell Lung Cancer ( SCLC ), CAR-T Cell Therapy
TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC
This is a single-arm, open-label, dose-escalation clinical trial designed to evaluate the safety, tolerability, expansion, and persistence of TC-D101 CAR-T cells in patients with DLL3-positive Relapsed/Refractory primary small…
- Trial name
- NCT07246304
- Testing
- TC-D101 CAR-T
- Where
- China
- Volunteers
- 24 people
- Sponsor
- TCRCure Biopharma Ltd.
Melanoma
Haploidentical NK Cell Infusion in Malignant Melanoma
We hypothesized that haploidentical NK cells kill tumor cells more efficiently than autologous NK cells, based on the missing-self hypothesis.
- Trial name
- NCT00846833
- Testing
- Haploidentical NK cell
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Seoul National University Hospital
Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor
Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, ifosfamide, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma
- Trial name
- NCT00423852
- Testing
- filgrastim, carboplatin, ifosfamide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
MYOPATHY
Stem Cell Transplantation in Idiopathic Inflammatory Myopathy Diseases
Myositis is a disease, believed to be due to immune cells, cells which normally protect the body, but are now attacking the muscles and other organ systems within body.
- Trial name
- NCT00278564
- Testing
- Hematopoietic stem cell transplantation, Cyclophosphamide, Mesna
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Northwestern University
AML, ALL
Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders
The purpose of this study is to provide allogeneic stem cell transplantation to patients who have not traditionally undergone this procedure because of it high incidence of treatment related side effects.
- Conditions
- AML, ALL, CML Chronic Phase, Accelerated Phase, or Blast Crisis, CLL
- Trial name
- MINI HEME (NCT00636909)
- Testing
- Cyclophosphamide, fludarabine, cyclosporine
- Volunteers
- 25 people
- Sponsor
- Beth Israel Deaconess Medical Center
Breast Cancer
A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast Cancer
This study will assess the efficacy and safety of adding Herceptin to a paclitaxel-containing regimen followed by cyclophosphamide/methotrexate/fluorouracil (CMF) chemotherapy in women with locally advanced breast cancer and…
- Trial name
- NCT01998906
- Testing
- Trastuzumab, Doxorubicin, Paclitaxel
- Where
- 36 sites in Austria, Germany and 4 more
- Volunteers
- 330 people
- Sponsor
- Hoffmann-La Roche
Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation
G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT
Allo-HSCT is the most effective way to cure high-risk MDS patients. At present, the best conditioning regimen for high-risk MDS patients undergoing allo-HSCT remains in discussion.
- Conditions
- Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning
- Trial name
- NCT05453552
- Testing
- Granulocyte Colony-Stimulating Factor(G-CSF), Decitabine (DAC), Busulfan
- Where
- China
- Volunteers
- 242 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Metastatic Melanoma
Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma
Background: In a study in humans with melanoma, patients given total body irradiation to suppress the immune system in conjunction with chemotherapy showed a significant clinical response.
- Trial name
- NCT00314106
- Testing
- Melanoma Reactive TIL, Cyclophosphamide, IL-2
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
Long-Term Follow-up of Tandem High-Dose Therapy With Peripheral Blood Stem Cell for Adults With High-Risk Age-Adjusted IPI Aggressive Non-Hodgkin's Lymphomas
Phase II multicenter pilot trial (073) evaluating tandem HDT with PBSC support in aa-IPI=3 untreated aggressive NHL.
- Trial name
- 073 (NCT00869284)
- Testing
- CEEP regimen, Tandem high-dose therapy (HDT) followed by autologous peripheral blood stem cell (PBSC)
- Where
- France
- Volunteers
- 45 people
- Sponsor
- French Innovative Leukemia Organisation
Relapsed/Refractory Large B-cell Lymphoma
Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma
This study will have two Phases: Phase 1a and Phase 1b. The goal of Phase 1a of this clinical study is to learn more about the safety, tolerability and dosing of study drug KITE-197, in participants with relapsed or refractory…
- Trial name
- NCT06079164
- Testing
- KITE-197, Cyclophosphamide, Fludarabine
- Where
- 11 sites in United States, Australia and 1 more
- Volunteers
- 21 people
- Sponsor
- Kite, A Gilead Company
Relapsed T-Cell Acute Lymphoblastic Leukemia, Relapsed T-Cell Lymphoblastic Lymphoma
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Nelarabine has shown significant activity in patients with T-cell malignancies. This study will determine the safety and maximum tolerated dose of the combination of nelarabine, cyclophosphamide and etoposide in patients with…
- Trial name
- NCT00981799
- Testing
- Nelarabine, Etoposide, Cyclophosphamide
- Where
- 37 sites in United States, Australia and 5 more
- Volunteers
- 23 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Neutropenia, Sickle Cell Anemia
Study of Allogeneic Bone Marrow Transplantation Using Matched, Related Donors in Patients With Nonmalignant Hematologic Disorders
OBJECTIVES: I. Determine the efficacy of bone marrow transplantation using matched related donors in patients with nonmalignant hematologic disorders. II.
- Conditions
- Neutropenia, Sickle Cell Anemia, Thalassemia Major, Red-Cell Aplasia, Pure
- Trial name
- NCT00005893
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Sponsor
- Fairview University Medical Center
Leukemia, Lymphoma
Total-Body Irradiation, Cyclophosphamide, and Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Adjusting the dose of drugs used in chemotherapy such as cyclophosphamide may decrease side effects while stopping cancer cells from dividing so they stop growing or die.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00062140
- Testing
- cyclophosphamide, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center